BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi’s stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron’s laboratories.

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 2 new employees consisting of an aggregate of 135,000 stock options.

A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.

Wilmington, Delaware, United States, Transparency Market Research Inc.: A neonatal intensive care unit, also known as an intensive care nursery, is a specialized unit where ill or premature newborn babies who need intensive medical attention are admitted.

Clario, a technology company that delivers the leading endpoint solutions for decentralized, hybrid and site-based clinical trials, announced that the company’s new chief executive officer, Christopher Fikry, M.D., previously introduced on June 7, 2022

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD).

Teva Pharmaceutical Industries Ltd. announced the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors.

Vaxart, Inc. urges its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so.

IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter™ single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy.